2024
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Otero P, Bermúdez M, Martin T, Santoro A, Yee A, Creignou M, Rodriguez C, Cerchione C, De La Rubia J, Oriol A, Waibel H, Besemer B, Thompson E, Kiesel B, Chen J, Chung A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood 2023, 142: 2011. DOI: 10.1182/blood-2023-180013.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaTreatment-emergent adverse eventsT-cell engagersLines of therapyOverall response ratePhase 1 studyTarget dosesTarget doseMedian PFSData cutoffMedian timeSafety profileCD3 T-cell engagerUpper respiratory tract infectionAnti-CD38 therapyAntitumor activityGrade 1 neurotoxicityTreatment-related deathsCytokine release syndromeRefractory multiple myelomaRespiratory tract infectionsPhase 1 trialPopulation pharmacokinetic analysisHuman clinical studiesObserved trough concentrationsP-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Costa L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.Peer-Reviewed Original ResearchP883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY
Wong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.Peer-Reviewed Original Research
2022
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong S, Bar N, Paris L, Hofmeister C, Hansson M, Santoro A, Mateos M, Rodríguez-Otero P, Lund J, Encinas C, Yee A, Oriol A, Cerchione C, de la Rubia J, Ferstl B, Carlson K, Ribas P, Bermúdez A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. Blood 2022, 140: 400-402. DOI: 10.1182/blood-2022-159009.Peer-Reviewed Original Research